Glatiramer acetate: successful desensitization for treatment of multiple sclerosis

Bains, Sonia N.; Hsieh, Fred H.; Rensel, Mary; Radojicic, Cristine; Katz, Hary T.; Inamdar, Swati; Lang, David M.

doi:10.1016/j.anai.2009.11.040

Cited by 15 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,75 Subcutaneous desensitization with GA has been shown to be effective in patients with focal and systemic reactions, enabling them to return to therapy without further reactions. 71 Indurations, swelling, and rashes may respond to cortisone cream; however, in cases of necrosis, cortisone can delay the healing process and increase the likelihood of secondary infections. Betamethasone valerate 0.1% cream is recommended for ISRs because the level of cortisone is high enough to manage inflammation but low enough to prevent additional problems.…”

Section: Management Of Injection-site Infectionsmentioning

confidence: 99%

“…62,70 There have been case reports of focal and diffuse urticaria and pruritus occurring within 30 minutes to several months after the initiation of GA, as well as a single case of urticarial vasculitis. 71,72 The reason for rash formation is unknown, but it has been suggested that MS patients have abnormalities of platelet activation and that IFNβ may enhance platelet aggregation in these patients, causing a platelet-dependent thrombosis. 62 The literature contains little information on lumps, swelling, and redness associated with DMTs in MS.…”

Section: Management Of Injection-site Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Best Practices in Skin Care for the Multiple Sclerosis Patient Receiving Injectable Therapies

McEwan¹,

Brown²,

Poirier³

et al. 2010

International Journal of MS Care

View full text Add to dashboard Cite

Although a cure for multiple sclerosis (MS) has not yet been discovered, a number of treatment options are available to help control symptoms, slow disease progression, and improve quality of life in patients with relapsing-remitting MS (RRMS). These include disease-modifying therapies (DMTs) such as beta-interferons, glatiramer acetate, and natalizumab. Disease-modifying therapies requiring frequent, self-administered injections can be particularly troublesome for some patients, as they may result in localized skin reactions at the injection site. A variety of injection-site reactions (ISRs) have been reported, including pain and erythema, lipoatrophy, abscesses and infections, necrosis, rash, swelling, and lumps. In order to appropriately distinguish between normal and abnormal reactions and to determine when further intervention is required, nurses involved in the care of patients with MS should be knowledgeable about the potential ISRs associated with DMTs. This best practices document was developed by a panel of Canadian MS clinic nurses in order to increase recognition among nurses that MS patients are at high risk for skin-site reactions with injectable therapies, and to provide the basis for skin-care practices in these patients. It reviews the risk factors associated with adverse skin reactions in MS patients treated with injectable therapies; the current attitudes and beliefs of nurses with respect to skin care; and the optimal skin-care interventions for MS patients at risk for adverse skin reactions when treated with injectable therapies. Areas requiring further research are discussed.

show abstract

Section: Management Of Injection-site Infectionsmentioning

confidence: 99%

Section: Management Of Injection-site Infectionsmentioning

confidence: 99%

Best Practices in Skin Care for the Multiple Sclerosis Patient Receiving Injectable Therapies

McEwan¹,

Brown²,

Poirier³

et al. 2010

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…High dose immunoglobulin could be another possibility especially for patient #2 as already mentioned above. If GA should ever have to be re-introduced because of a lack of other neurologic treatment options, a successful desensitization protocol to GA has already been published [12,13].…”

Section: Discussionmentioning

confidence: 99%

Anaphylaxis to Glatiramer Acetate

Wöhrl¹,

Wantke²,

Hemmer³

2015

TOALLJ

View full text Add to dashboard Cite

Glatiramer acetate (Copaxone, Teva Pharma) and interferon beta are the two only disease-modifying therapies for multiple sclerosis. Glatiramer acetate is known for frequently simulating mild, anaphylactoid reactions while true, IgEmediated allergic reactions have been hardly reported so far. Herein, we report two females suffering from multiple sclerosis who experienced rapidly aggravating hypersensitivity-reactions upon treatment with glatiramer acetate. Patient one experienced an asthma attack, patient two an exacerbation of her urticaria and angioedema. An IgE-mediated mechanism could be demonstrated by a positive intradermal test to a 1:1000 dilution in the first 31-year old and by a positive skin prick test to a 1:10 diluted skin prick test in the second 32-year old second woman.

show abstract

“…Desensitization protocols for glatiramer acetate have been previously reported in adult patients. A first report in 2010 described a protocol that was successfully applied in six adult patients with history of either immediate or delayed systemic reactions (9). A similar, more gradual version of that desensitization protocol, which included premedication with steroids and antihistamines, was subsequently used in another adult patient (10).…”

Section: Ige-mediated Hypersensitivity Reaction and Desensitization Tmentioning

confidence: 99%

IgE‐mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient

Crestani

Lee

Gorman

et al. 2014

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Glatiramer acetate: successful desensitization for treatment of multiple sclerosis

Cited by 15 publications

References 17 publications

Best Practices in Skin Care for the Multiple Sclerosis Patient Receiving Injectable Therapies

Best Practices in Skin Care for the Multiple Sclerosis Patient Receiving Injectable Therapies

Anaphylaxis to Glatiramer Acetate

IgE‐mediated hypersensitivity reaction and desensitization to glatiramer acetate in a pediatric patient

Contact Info

Product

Resources

About